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In the current issue of Cell Metabolism, Arany et al. (2005) demonstrate essential roles for PGC-1α in cardiac metabolism,
proving several long-postulated functions while disproving others. These experiments conclusively reinforce the logic of
rescuing PGC-1α as a novel therapeutic target in heart failure.Metabolic pathways are modulated in re- p
sponse to biological and pathobiologi- g
pcal circumstances, through mechanisms
ranging from altered protein function or i
gtrafficking to transcription and chromatin
remodeling (Kelly and Scarpulla, 2004). e
MSpecific transcription factors directly bind
a subset of protein-coding genes, while P
2general transcription factors directly bind
to all transcribed genes; transcriptional
dcoactivators and corepressors are teth-
ered to genes indirectly, through interac- f
ttions with the DNA bound factors. In the
effort to disentangle the circuits con- p
dtrolling energy homeostasis, peroxisome
proliferator activated receptor-γ coactiva- b
mtor-1α (PGC-1α), a cold-inducible coacti-
vator of nuclear hormone receptors, holds s216articular interest (Puigserver and Spie- o
belman, 2003). Despite a plethora of sup-
orting data, conclusive genetic proof of o
mts function has been lacking for most or-
ans in which PGC-1α is expressed (Lin s
rt al., 2004). New work in this issue of Cell
etabolism sheds light on the role of t
oGC-1α in cardiac function (Arany et al.,
005). f
LPGC-1α expression is dynamic—in-
uced by cold, short-term exercise, and p
basting, for example—and in these set-
ings PGC-1α is thought to coordinate ex- 2
ression of genes controlling mitochon-
rial biogenesis and thermogenesis in e
erown fat, fiber-type switching in skeletal
uscle and gluconeogenesis in liver (Puig- a
merver and Spiegelman, 2003). PGC-1αrchestrates a transcriptional network,
inding nuclear hormone receptors and
ther transcription factors, chromatin re-
odeling proteins such as p300 and
teroid receptor coactivator-1, the thy-
oid receptor-associated protein/Media-
or complex, and the “elongating” form
f RNA polymerase II, bound to splicing
actors (Puigserver and Spiegelman, 2003;
in et al., 2004; Arany et al., 2005). Phos-
horylation and deacetylation of PGC-1α
oth modulate its function (Fan et al.,
004; Rodgers et al., 2005).
In the heart, where the balance of en-
rgy production and consumption is lit-
rally vital, PGC-1α is postulated to play
critical role for genes underlying the
itochondrial ATP-generating pathway,CELL METABOLISM : APRIL 2005
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Figure 1. PGC-1α is essential for cardiac metabolism and work output
m
Circuits for PGC-1α expression and function in cardiac muscle are depicted. Signal transduction pathways
mthat mediate increased workload on the heart (e.g., hypertension or experimental aortic constriction) both
Wstimulate PGC-1α expression, via myocyte enhancer factor-2 (MEF2), and repress PGC-1α, via cyclin-depen-
dent kinase-9 (Cdk9). MEF2 becomes activated through calcium-dependent phosphorylation and dissociation h
of class II histone deacetylases (HDACs). Cdk9 becomes activated by dissociation of an endogenous inhibitor, c
tethered by the 7SK small nuclear RNA. Effectors responsible for the essential role of PGC-1α in myocardial h
energy creation likely include PPARs, estrogen-related receptors (ERR), nuclear respiratory factors (NRF), and
cmitochondrial transcription factor A (Tfam), in addition to MEF2. Defective mitochondrial enzyme expression
impairs cardiac energetics and, consequently, cardiac mechanical performance. Gq, heterotrimeric G protein B
Gq. CaMK, calmodulin-dependent protein kinase. a
tCELL METABOLISM : APRIL 2005orking through PPARs, estrogen-related
eceptors, nuclear respiratory factors, and
uscle enhancer factor-2 (MEF2) (Huss
nd Kelly, 2005). In contrast to its role
ncoupling mitochondrial respiration in
rown fat for greater heat production,
GC-1α increases cardiac mitochon-
rial respiration to maintain the heart’s
nceasing mechanical performance. In
ain-of-function studies that were the
trongest previous evidence, overexpress-
ng PGC-1α in cultured cardiomyocytes
nd mouse myocardium upregulated a
arge ensemble of genes important for
atty acid oxidation, the tricarboxylic
cid (TCA) cycle, respiratory chain com-
lexes, and mitochondrial proliferation
Lehman et al., 2000; Huss and Kelly,
005). These findings support the inter-
retation that this coactivator is limiting
nd suggest that biological changes in
GC-1α expression are likely to have
unctional impact. But forced expression
aused contractile dysfunction and a di-
ated heart, ascribed to mitochondrial
yperproliferation. Because forced ex-
ression inherently cannot prove the
ssential functions of a protein at typical
bundance and activity, the outcome of
oss-of-function studies would seem es-
ecially informative.
Cardiac growth after birth occurs pri-
arily through cell enlargement (hyper-
rophy). The dichotomy of “physiologi-
al” versus “pathological” hypertrophy,
lthough simplistic, has some value.
ostneonatal maturational growth and
xercise-induced growth, examples of
he former, augment cardiac output to
eet increased demand, without appar-
nt deleterious effect. In contrast, path-
logical hypertrophy due to hypertension
nd other mechanical stress, cardiac
ene mutations, or the need to supplant
nfarcted myocardium may maintain
ump function early on but can progress
o heart failure if protracted or severe
Olson and Schneider, 2003). Under nor-
al conditions, fatty acids (richer than
lucose) are the preferred energy source
f adult cardiomyocytes; along with high
itochondrial density, this is critical to
eeting the cells’ ATP requirements.
hereas physiological hypertrophy en-
ances fatty acid oxidation and mito-
hondrial volume, during pathological
ypertrophy a switch occurs, and glu-
ose becomes the preferred substrate.
ecause this requires less oxygen, such
shift may be beneficial in acute situa-
ions such as in ischemia. Chronically,217
P R E V I E Wdecreased energy production plus ineffi- m
cient ATP utilization might exacerbate t
sthe slip into decompensated hypertro-
phy. Unsurprisingly, PGC-1α is upregu-
plated during maturational growth but
idownregulated in pressure-challenged
oand failing hearts (reviewed in Arany et
aal., 2005).
dThe signals upregulating PGC-1α in
cskeletal muscle are well characterized (Lin
met al., 2002). Chronic exercise induces
nthe conversion of muscle fibers from
sglycolytic (fast twitch) to oxidative (slow
Atwitch), characterized by increased mito-
schondrial number, oxidative metabolism,
emyoglobin, and specific “slow” con-
Ptractile protein isoforms. Instrumental to
mthis fiber-switching program, calcium/cal-
smodulin-dependent protein kinase IV
tand likely equivalent kinases induce the
wnuclear export of class II histone de-
oacetylases that otherwise act as core-
2pressors of MEF2. Consequently, MEF2
sbecomes active and PGC-1α is able to
wcoactivate MEF2-dependent genes. PGC-
d1α itself is induced by chronic physical
gactivity in skeletal muscle through this
csame MEF2/PGC-1α pathway.
oFor cardiac muscle, mechanisms by
m
which “physiological” and “pathophysio-
a
logical” cues differentially regulate PGC-
t
1α have only begun to be resolved. A sig- P
nal-resistant mutation of HDAC5 and f
deleting MEF2A each downregulate PGC- A
1α and disrupt cardiac mitochondrial p
function, suggesting a central role for the (
HDAC/MEF2/PGC-1α pathway (Czubryt a
et al., 2003). BecauseMEF2 is strongly ac- p
tivated in pathological hypertrophy (Olson c
and Schneider, 2003), it is arguably para- c
doxical that PGC-1α is downregulated in w
this setting. A discrepancy between MEF2 s
activation and PGC-1α suppression can w
be reconciled most easily by the exis- b
tence of concomitant suppressors. One P
such suppressor was recently discov- a
ered: cardiac cyclin T/Cdk9 activity is in-
creased in multiple forms of hypertrophy d
through the dissociation of an endoge- i
nous inhibitor and selectively downregu- m
lates PGC-1α expression at or prior to c
preinitiation complex formation (Sano et p
al., 2004). This predisposes cardiac mus- l
cle to apoptosis when challenged by in- m
creased workload or Gαq-dependent sig- f
nals (Figure 1). Cdk9, which is directed c
against RNA polymerase II itself, is best 1
pknown for its effects on generalized pro-218oter escape. However, cyclin T is known t
oo couple Cdk9 to a number of gene-
pecific factors. u
tGiven the suppression of PGC-1α in
athological cardiac hypertrophy, but keep- s
ng in mind the counterintuitive gain- p
f-function studies, does loss of PGC-1α o
ctually provoke the imputed mitochon-
rial defects? Arany et al. have now M
haracterized the cardiac and skeletal a
uscles of PGC-1α−/− mice, an engi- 1
2eered strain known to be lean, cold sen-
itive, and hyperactive (Lin et al., 2004;
3rany et al., 2005). The results are a
ubtly instructive admixture of “proph-
Ccy fulfilled” and “prophecy denied.”
GC-1α was dispensable both for nor-
B
al mitochondrial number in these tis- H
ues and for specification of oxida-
ive skeletal muscle fibers, functions to
hich ectopic expression attested vig- S
rously (Lin et al., 2002; Lehman et al.,
A000). By contrast, levels of gene tran-
C
cripts related to mitochondrial function P
ere deficient, especially in myocar- 2
ium, where PGC-1α targets included
C
enes for oxidativephosphorylation en- O
oded by the nucleus (cox5b), genes for 1
xidative phosphorylation encoded by
F
itochondria (cybmm), genes for fatty P
cid oxidation (cpt2), and mitochondrial m
(ranscription factors (Tfam). Lack of
GC-1α also caused corresponding de- H
ects in mitochondrial enzyme activities, 1
TP and phospho-creatine levels, basal
K
ump function, and contractile reserve D
cardiac mechanical performance after
Ldrenergic stimulation or rapid electrical
J
acing). The results conclusively impli- C
ate PGC-1α as a critical regulator of
Lardiac ATP generation and cardiac B
ork. That the phenotype is not more O
evere, namely that overt heart failure
Las not the result, might be explained P
y redundant coactivators, of which V
GC-1β and PGC-1-related coactivator (
re but one category. O
Considering the now clear-cut depen- D
ence of cardiac muscle on PGC-1α, it
P
s tempting to speculate how best to d
ove present knowledge toward suc-
Ressful application. Conceptually sim-
S
lest to implement, and amenable at t
east to a key group of major targets,
Sight be to exploit existing agonists
M
or PPARγ. A longer-term approach dis- P
ussed by Arany et al. is to rescue PGC- 3
α expression in pathological hypertro-
hy, provided this can be done without Dhe excessive mitochondrial proliferation
f past transgenic studies (e.g., without
nduly displacing sarcomeres). In addi-
ion to rescue by gene transfer, thought
hould be given to suppressing the sup-
ressors: cyclin T/Cdk9, HDACs, and
thers that may emerge.
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